 Sovodak 60/400 | |
| Combination of | |
|---|---|
| Daclatasvir | NS5A inhibitor |
| Sofosbuvir | NS5B (RNA polymerase) inhibitor |
| Clinical data | |
| Trade names | Darvoni, Sovodak |
| Routes of administration | By mouth |
| Drug class | Combination direct-acting antiviral |
Daclatasvir/sofosbuvir (SOF/DCV), sold under the brand name Sovodak among others, is a combination medication used to treat hepatitis C.[1] It is a first line treatment and is effective against all subtypes.[3] It is more than 90% effective.[1] It may be used in those who are at least 3 years old.[4] It is generally take by mouth once per day for 12 weeks as either a single pill or separately.[2][1]
Common side effects include headache, tiredness, nausea, and abdominal pain.[2] Serious side effects are uncommon.[2] Use of daclatasvir and sofosbuvir has not been found to be harmful in pregnancy but has not been well studied.[5][6] It contains daclatasvir, a viral NS5A inhibitor,[7] and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.[8]
It is the most commonly used treatment for hepatitis C in low and middle income countries as of 2022.[3] The combination has never been approved in the United States and sale of daclatavir was stopped their in 2019.[9] It is on the World Health Organization's List of Essential Medicines.[10] It is the least expensive modern hepatitis C treatment, with costs from 50 to 1,400 USD.[2][3]
References edit
- ^ a b c d Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–26. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c d e "Application for Inclusion of Sofosbuvir/Daclatasvir on the WHO Model List of Essential Medicines for Children (EMLc)" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 2 December 2022.
- ^ a b c "Hepatitis C". www.who.int. Archived from the original on 26 May 2020. Retrieved 2 December 2022.
- ^ "WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics". www.who.int. Archived from the original on 6 October 2022. Retrieved 2 December 2022.
- ^ "Daclatasvir (Daklinza) Use During Pregnancy". Drugs.com. Archived from the original on 6 December 2021. Retrieved 2 December 2022.
- ^ "Sofosbuvir (Sovaldi) Use During Pregnancy". Drugs.com. Archived from the original on 5 February 2020. Retrieved 2 December 2022.
- ^ "Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.
- ^ "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- ^ Abraham, GM; Obley, AJ; Humphrey, LL; Qaseem, A; Scientific Medical Policy Committee of the American College of, Physicians; Centor, RM; Akl, E; Forceia, MA; Haeme, R; Hamilton, PG; Hood, GA; Jokela, JA; Kansagara, DL; Levine, MA; Mason, JR; Marcucci, M (January 2021). "World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians". Annals of internal medicine. 174 (1): 98–100. doi:10.7326/M19-3860. PMID 33017566.
{{cite journal}}:|last5=has generic name (help) - ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.